Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Oncolys’ Telomelysin Up for Japan Panel Review on May 21
A Japanese health ministry panel will meet on May 21 to discuss whether to recommend approval for Oncolys BioPharma’s oncolytic virus therapy telomelysin for esophageal cancer. The Pharmaceutical Affairs Council’s Committee on Regenerative Medicine Products, Biological Products and Biotechnologies is…
To read the full story
Related Article
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Oncolys Targets 300 Hospitals for Telomelysin Rollout
June 9, 2026
- Oncolys’ Telomelysin Wins Backing from Japan Panel
May 22, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
REGULATORY
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- Atopic Dermatitis Proactive Therapy to Be Exempt from OTC-Like Drug Charge
September 14, 2026
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…